672 results match your criteria: "Lou Ruvo Center for Brain Health[Affiliation]"
JAMA Netw Open
September 2024
Institute for Translational Research, University of North Texas Health Science Center, Fort Worth.
Importance: Determining the influence of race and ethnicity on change in cognitive test performance has significant implications for clinical practice and research in populations at risk for Alzheimer disease.
Objective: To evaluate the significance of race and ethnicity in predicting longitudinal cognitive test performance and to develop models to support evidence-based practice.
Design, Setting, And Participants: This prognostic study included baseline and 24-month follow-up data that were obtained from the Health and Aging Brain Study-Health Disparities (HABS-HD) study, an ongoing longitudinal observational study of aging and dementia in a multiracial, multiethnic cohort.
JAMA Netw Open
August 2024
Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Neurol Clin Pract
December 2024
Neuroscience Institute (MKB), The Queen's Medical Center; Medicine (MKB), University of Hawaii, John A Burns School of Medicine, Honolulu; Neurology (RD), University of Arkansas for Medical Sciences, Little Rock; Service de Neurologie (AD), Département de Médecine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Neurology (IUH), University of Miami, FL; Neurology (LSH), Columbia University Irving Medical Center, New York; Neurology (GL), The University of Utah; Neurology (GL), George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT; Neurology (NRM), University of Florida, Gainesville; Neurology (LM-K), Brigham and Women Hospital and Harvard Medical School, Boston, MA; Neurology (ZM), Johns Hopkins University, Baltimore, MD; Cleveland Clinic Lou Ruvo Center for Brain Health (ZM), Las Vegas, NV; Neurology (FR-P), Medical University of South Carolina, Charleston; CurePSP (J. Shurer, KD, LIG), New York; Neurological Institute (J. Siddiqui), Cleveland Clinic, OH; Neurology (CCS), University of Michigan, Ann Arbor; Neurology (AMW), Massachusetts General Hospital and Harvard Medical School, Boston; and Neurology (LIG), Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Purpose Of Review: The most common four neurodegenerative atypical parkinsonian disorders (APDs) are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). Their formal diagnostic criteria often require subspecialty experience to implement as designed and all require excluding competing diagnoses without clearly specifying how to do that. Validated diagnostic criteria are not available at all for many of the other common APDs, including normal pressure hydrocephalus (NPH), vascular parkinsonism (VP), or drug-induced parkinsonism (DIP).
View Article and Find Full Text PDFIntroduction: Informed decisions to enrol in the clinical investigations of Alzheimer's disease and related dementias (ADRD) require careful consideration of complex risks and uncertain benefits. Decisions regarding whether to receive information about biomarker status are complicated by lack of scientific consensus regarding biomarkers as surrogate endpoints for Alzheimer's disease and how information about individual risk should be evaluated and shared with research participants. This study aims to establish stakeholder consensus regarding ethically optimal approaches to sharing individual results with ADRD research participants.
View Article and Find Full Text PDFNeuroscience
November 2024
Department of Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA; Department of Psychology and Neuroscience, University of Colorado, Boulder, CO 80309, USA.
Olfactory dysfunction is an early sign of such neurodegenerative diseases as Parkinson's (PD) and Alzheimer's (AD), and is often present in Mild Cognitive Impairment (MCI), a precursor of AD. Understanding neuro-temporal relationships, i.e.
View Article and Find Full Text PDFNeurol Clin Pract
October 2024
Department of Rehabilitation Medicine (HA, OJ), New York University Grossman School of Medicine, New York, NY; NYU Concussion Center (HA), NYU Langone Health, New York, NY; Psychiatry Neuroimaging Laboratory (HA, LBJ, OJ, NK, HWC, EK, AC, TLTW, TB, OP, MJC, IKK, SB, MES), Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; cBRAIN (LBJ, TLTW, IKK), Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit¨at, Munich, Germany; Department of Biostatistics (FT-Z, YT), Boston University School of Public Health Boston, MA; Center for Clinical Spectroscopy (KB, APL), Department of Radiology, Brigham and Women's Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Harvard Medical School Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Massachusetts General Hospital Boston, MA; Department of Physical Medicine and Rehabilitation (DD), Spaulding Rehabilitation Hospital, Cambridge, MA; Department of Radiology (OP, APL, MES), Brigham and Women's Hospital, Harvard Medical School Boston, MA; Department of Psychiatry (OP, IKK, MES), Massachusetts General Hospital Boston, MA; Department of Neurology (CHA), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV (CB); Department of Neurology (CB), University of Washington, Seattle, WA; Department of Neurology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Population Health (LJB), New York University Grossman School of Medicine, New York, NY; Department of Ophthalmology (LJB), New York University Grossman School of Medicine, New York, NY; Department of Neurology (MLA, RAS), Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA; Graduate School of Systemic Neurosciences (IKK), Ludwig-Maximilians-Universität, Munich, Germany; Chambers-Grundy Center for Transformative Neuroscience (JLC), Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV; Banner Alzheimer's Institute and Arizona Alzheimer's Consortium (EMR), Phoenix, AZ; Department of Psychiatry (EMR), University of Arizona, Tucson, AZ; Department of Psychiatry (EMR), Arizona State University, Phoenix, AZ; Neurogenomics Division (EMR), Translational Genomics Research Institute and Alzheimer's Consortium, Phoenix, AZ; Department of Anatomy and Neurobiology (RAS); Department of Neurosurgery (RAS), Boston University Chobanian & Avedisian School of Medicine, Boston, MA; and Department of Software Engineering and Information Technology (SB), École de technologie supérieure, Université du Québec, Montreal, Canada.
Parkinsonism Relat Disord
September 2024
Parkinson Disease and Movement Disorders Program, Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W. Bonneville Avenue, 89106, Las Vegas, NV, United States. Electronic address:
Neurology
September 2024
From the Departments of Neurology (J.G., A.S.C.-P., N.D., J.M., A.D.S., A.W.W., D.W.) and Psychiatry (E.M., D.W.), and Biostatistics and Epidemiology (S.X.X.), University of Pennsylvania, Philadelphia; Department of Biostatistics (C.G., C.C.-G., C.S.C.), University of Iowa; Department of Psychiatry (R.D.D.), Rutgers University, Newark, NJ; Department of Old Age Psychiatry (D.A.), Kings College London, UK; Neurological Institute (R.N.A.), Tel Aviv Sourasky Medical Center, Israel; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Department of Neurology (M.J.B.), Virginia Commonwealth University, Richmond, VA; Department of Neurology (L.C.), University of Pittsburgh, PA; The Michael J. Fox Foundation for Parkinson's Research (J.L.E.), New York, NY; James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E.), Department of Neurology, University of Cincinnati; Cleveland Clinic (J.B.L.), Neurological Institute, Lou Ruvo Center for Brain Health, OH; Department of Neuroscience (I.L.), University of California San Diego; Parkinson's Disease Research, Education and Clinical Center (PADRECC) (J.M., D.W.), Crescenz Veteran's Affairs Medical Center, Philadelphia, PA; Department of Neurology (I.H.R.), University of Rochester, NY; Department of Neurology (L.R.), Johns Hopkins University, Baltimore, MD; and Department of Neurology (T.S.), Northwestern University, Chicago, IL; Departments of Neurology and Psychiatry and Behavioral Sciences (M.K.Y.), Baylor College of Medicine, Houston, TX.
Neurol Res Pract
August 2024
Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Introduction: Given the prevalence and staggering cost of neurological disorders, there is dire need for effective early detection and intervention tools. Emerging evidence suggests that multidisciplinary lifestyle interventions (MLI) may mitigate the risk and progression of neurological disorders. The objectives of this protocol are (1) to test the impact of MLI on the progression of neurological disorders and (2) to identify multi-omic biomarkers for early stages of neurological disease and the impact of MLIs on these biomarkers.
View Article and Find Full Text PDFFront Dement
August 2023
Memory & Cognitive Disorders Program, Hoag Hospital, Pickup Family Neurosciences Institute, Newport Beach, CA, United States.
Introduction: Rural-dwelling older adults face unique health challenges that may increase risk for Alzheimer's disease and dementia but are underrepresented in aging research. Here, we present an initial characterization of a rural community cohort compared to an urban cohort from the same region.
Methods: Adults over age 50 living in a non-metropolitan area are clinically characterized using the Uniform Data Set, enriched with additional measures of verbal and non-verbal memory measures.
J Neuropsychiatry Clin Neurosci
January 2025
Chronic Traumatic Encephalopathy Center (Pulukuri, Fagle, Trujillo-Rodriguez, van Amerongen, Katz, Alosco, Tripodis, Stern), Graduate Program in Neuroscience (Trujillo-Rodriguez), Department of Neurology (Katz, Alosco, Stern), Alzheimer's Disease Research Center (Alosco, Tripodis, Stern), Department of Neurosurgery and Department of Anatomy and Neurobiology (Stern), Boston University Chobanian and Avedisian School of Medicine, Boston; Department of Neurology, Alzheimer Center Amsterdam, Vrije Universiteit (VU) Amsterdam, VU University Medical Center, and Department of Neurodegeneration, Amsterdam Neuroscience, Amsterdam (van Amerongen); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (Bernick); Department of Neurology and the Franke Global Neuroscience Education Center, Barrow Neurological Institute, Phoenix (Geda); Department of Psychiatry and Psychology (Wethe) and Department of Neurology (Adler), Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale; Veterans Affairs Northwest Mental Illness Research, Education, and Clinical Center and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (Peskind); Brain Injury Program, Encompass Health Braintree Rehabilitation Hospital, Braintree, Mass. (Katz); Biostatistics and Epidemiology Data Analytics Center (Palmisano) and Department of Biostatistics (Tripodis), Boston University School of Public Health; Departments of Neurology, Population Health, and Ophthalmology, New York University Grossman School of Medicine, New York (Balcer); Banner Alzheimer's Institute, University of Arizona, Translational Genomics Research Institute, Arizona State University, and Arizona Alzheimer's Consortium, Phoenix (Reiman); Departments of Psychiatry and Radiology, Psychiatry Neuroimaging Laboratory, Harvard Medical School, Brigham and Women's Hospital, Boston (Shenton); Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, School of Integrated Health Sciences, University of Nevada Las Vegas (Cummings).
Background: White matter signal abnormalities have been associated with traumatic brain injury (TBI) and repetitive head impacts (RHI) in contact sports (e.g. American football, rugby).
View Article and Find Full Text PDFNeurology
August 2024
From the Joi Life Wellness MS Center (M.J.W.), Atlanta, GA; University of Southern California (L.A.), Los Angeles; Providence Multiple Sclerosis Center (S.L.C.), Providence Brain and Spine Institute, Portland, OR; Cleveland Clinic Mellen Center (J.A.C.) OH; Department of Neurology (S.R.D.), University of Miami Miller School of Medicine, FL; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Novartis Pharmaceuticals Corporation (E.B.L., R.S.P., J.S.), East Hanover, NJ; and Envision Pharma, Inc. (C.R.K.), Horsham, United Kingdom.
Background And Objectives: Race and ethnicity may influence the efficacy of disease-modifying therapies in patients with multiple sclerosis (MS). Incidence of MS in ethnically diverse groups may be higher; however, these populations are under-represented in MS trials. This post hoc analysis compared the proportion of patients achieving 3-parameter no evidence of disease activity (NEDA-3) with ofatumumab vs teriflunomide in participants with relapsing MS (RMS) enrolled in the ASCLEPIOS I/II trials by race/ethnicity subgroup.
View Article and Find Full Text PDFJ Alzheimers Dis
August 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Conventional normative samples include individuals with undetected Alzheimer's disease neuropathology, lowering test sensitivity for cognitive impairment.
Objective: We developed Mayo Normative Studies (MNS) norms limited to individuals without elevated amyloid or neurodegeneration (A-N-) for Rey's Auditory Verbal Learning Test (AVLT). We compared these MNS A-N- norms in female, male, and total samples to conventional MNS norms with varying levels of demographic adjustments.
NPJ Digit Med
July 2024
Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Parkinson's disease (PD) is a serious neurodegenerative disorder marked by significant clinical and progression heterogeneity. This study aimed at addressing heterogeneity of PD through integrative analysis of various data modalities. We analyzed clinical progression data (≥5 years) of individuals with de novo PD using machine learning and deep learning, to characterize individuals' phenotypic progression trajectories for PD subtyping.
View Article and Find Full Text PDFJ Alzheimers Dis
August 2024
Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
J Alzheimers Dis
August 2024
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Background: Computer-aided machine learning models are being actively developed with clinically available biomarkers to diagnose Alzheimer's disease (AD) in living persons. Despite considerable work with cross-sectional in vivo data, many models lack validation against postmortem AD neuropathological data.
Objective: Train machine learning models to classify the presence or absence of autopsy-confirmed severe AD neuropathology using clinically available features.
JAMA Netw Open
June 2024
Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Cogn Behav Neurol
September 2024
Department of Anthropology, University of Nevada Las Vegas, Las Vegas, Nevada.
Background: Impairment in semantic knowledge contributes to Alzheimer disease (AD)-related decline. However, the particulars of the impact AD has on specific domains of knowledge remain debatable.
Objective: To investigate the impact of AD on specific semantic categories that are integral to daily functions-living things and man-made objects.
Dement Geriatr Cogn Disord
October 2024
Department of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.
Introduction: Cerebral amyloid angiopathy (CAA) is characterized by amyloid β (Aβ) deposition in brain vessels, leading to hemorrhagic phenomena and cognitive impairment. Magnetic resonance imaging (MRI)-based criteria allow a diagnosis of probable CAA in vivo, but such a diagnosis cannot predict the eventual development of CAA.
Methods: We conducted a retrospective cohort study of 464 patients with cognitive disorders whose data were included in a brain health biobank.
Lancet Neurol
July 2024
Mental Health, Dementia and Neurodegeneration Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Introduction: The development and progression of Alzheimer's disease (AD) is a complex process, during which genetic influences on phenotypes may also change. Incorporating longitudinal phenotypes in genome-wide association studies (GWAS) could unmask these genetic loci.
Methods: We conducted a longitudinal GWAS using a varying coefficient test to identify age-dependent single nucleotide polymorphisms (SNPs) in AD.
Neurol Clin Pract
August 2024
Neurological Institute (LMH, RG, TR), Section of Neuropsychology; Mellen Center for Multiple Sclerosis (RG, DO); Department of Biomedical Engineering (KN), Lerner Research Institute, Cleveland Clinic, OH; Lou Ruvo Center for Brain Health (BL, JBM, LHH), Cleveland Clinic, Las Vegas; College of Osteopathic Medicine (BL), Touro University, Henderson, NV; and Lou Ruvo Center for Brain Health (KK), Cleveland Clinic, OH.
Background And Objectives: Up to 65% of people with multiple sclerosis (MS) experience disease-related cognitive impairment, but even after decades of research, still very little is known about the cognitive issues among older adults with MS (EwMS; individuals aged 60+). To date, few studies have attempted to characterize cognitive impairment in this group or compare EwMS with those with other neurodegenerative diseases. Our goal was to address this knowledge gap by comparing EwMS with individuals experiencing cognitive impairment due to probable Alzheimer disease (AD) with biomarker confirmation.
View Article and Find Full Text PDFJ Neurol Phys Ther
July 2024
Physical Therapy, Touro University, Henderson, Nevada (M.S.); Cleveland Clinic Lou Ruvo Center for Brain Health (K.J.), Center for Neurorehabilitation Sciences, Sargent College of Health & Rehabilitation Sciences, Boston University, Boston, Massachusetts (K.J.).
Front Neurol
April 2024
Lou Ruvo Center for Brain Health, Neurological Institute Cleveland Clinic, Cleveland, OH, United States.
In addition to Alzheimer's disease (AD), the hippocampus is now known to be affected in variants of frontotemporal degeneration (FTD). In semantic variant primary progressive aphasia (svPPA), characterized by language impairments, hippocampal atrophy is greater in the left hemisphere. Nonverbal impairments (e.
View Article and Find Full Text PDF